Atezolizumab,nivolumab,Pembrolizumab,Ipilimumab
merck,roche,bms
['ipi/', 'nivo', 'renal,(-adrenal)', 'pembro']
summarising data from the adjuvant renal cancer trials is tricky #esmo22 it is likely to be due to multiple factors -trial design, the drug, the toxicity etc. it s unlikely pembrolizumab was positive by chance alone. pd-l1 inhibitors maybe less good here, but why was ipi/nivo -ve 
Interested in Urology Cancers, biomarkers and drug development.